RNA
Atrium Therapeutics, Inc. Healthcare Biotechnology
11/12
Innovation Score
Patent Activity
3/3
21 patents found
ALIAS_FUZZY
Cash Runway
3/3
52 months of cash remaining based on current burn rate.
Cash on hand: $267.8M
Cash on hand: $267.8M
Revenue Trajectory
3/3
Revenue: $36.7M
YoY Growth: +1148.3%
YoY Growth: +1148.3%
Management Quality
2/3
Insider ownership: 7.9%
SBC/Revenue: 0.0%
No reverse splits detected
SBC/Revenue: 0.0%
No reverse splits detected
Key Metrics
Market Cap
$225.6M
Revenue
$36.7M
Revenue Growth (YoY)
+1148.3%
Cash on Hand
$267.8M
Cash Runway
52 months
Shares Outstanding
17.1M
Insider Ownership
7.9%
SBC / Revenue
0.0%
Sector / Industry
Healthcare / Biotechnology
Patents (21)
Match type: ALIAS_FUZZY
- Compositions and methods for treating ornithine transcarbamylase deficiency
- Molecules and agents for treating hepatitis B virus
- Coronavirus vaccine compositions and methods
- Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugates
- Method of lyophilizing lipid nanoparticles
7-Step Risk Assessment
How RNA maps to our micro cap methodology:
- Innovation Signal 21 patents identified. This suggests the company is investing in defensible IP.
- Cash Runway Check 52 months of runway. Comfortable buffer for execution.
- Revenue Trajectory +1148.3% YoY growth on $36.7M revenue. Strong growth trajectory.
- Management Alignment Insiders hold 7.9% of shares. SBC is 0.0% of revenue.
- Competitive Moat Review the company's 10-K for barriers to entry: patents, network effects, switching costs, regulatory approvals. This step requires manual research.
- Catalyst Identification Look for upcoming catalysts: FDA decisions, contract wins, product launches, partnerships. Check recent 8-K filings and earnings transcripts.
- Position Sizing Micro caps carry outsized risk. Consider position sizing relative to conviction level and portfolio concentration. This is a $225.6M company.
Financial Detail
Free Cash Flow
N/A
FCF Yield
N/A
Return on Equity
N/A
Debt / Equity
1.1%
Gross Margin
-32.9%
Profit Margin
-160.0%
Operating Margin
-88.0%
Price / Book
0.96
Current Ratio
13.04
Dividend Yield
None
Share Count Change (YoY)
N/A
Share Count Change (3yr)
N/A
Quality Flags
Low Debt
Free Cash Flow Trend
Insufficient Data
Consecutive Years FCF Positive
0
Disclaimer: This is an automated screening tool, not investment advice. Micro cap stocks are inherently risky with low liquidity and high volatility. The innovation score is based on publicly available data and may not reflect the full picture. Steps 5-7 of the methodology require your own research. See our full disclaimer.
Last screened: 2026-06-27